Advertisement
"This is very important for TargetEx" -an emerging biotech company inHungary - "and an appreciation of our scientific potential " said SandorCseh, PhD., managing director. "We are excited to lead the consortium in theremaining phase of the project and we look forward to the exploitation of theexciting results and experience gathered in the effort of developing noveltechnologies and agents for cancer therapy."
Advertisement
"The CancerGrid consortium is an excellent combination of 11 Europeanresearch-oriented companies and academic centers integrating their bestpractices and specific knowledge including AMRI (USA/Hungary), Inte:Ligand(Austria), Tallinn University of Technology (Estonia), University of Helsinki(Finland), GKI Economic Research Co.(Hungary), Computer and AutomationResearch Institute (Hungary), DAC Srl and University of Bari (Italy),University Pompeu Fabra (Spain) and Hebrew University of Jerusalem (Israel)"added Istvan Bagyi, PhD., the project coordinator of CancerGrid.
Cancer is one of the major causes of death worldwide and developingsuccessful therapies is particularly challenging due to the high variabilityof cells, oncogenes and mutations. Developing tumor-cell specific cytotoxicagents is not only one of the aims of the CancerGrid project but also a"gentle" approache since they will attack only the cancer cells while notaffecting the healthy cellular functions.
"The primary objective of the multidisciplinary FP6 project is tointegrate various state-of-the art technologies including TargetEx'high-throughput differential cytotoxicity screening platform; in silicocompound library selection methods and QSAR model building accelerated withdistributed (grid) computing techniques. The ultimate goal of the project isto develop novel anti-cancer lead candidates together with a novel applicableresearch model which could cut the expenses and shorten the timeline ofanti-cancer drug discovery" gave further details Gyorgy Dorman, PhD. thescientific coordinator of CancerGrid.
"Entering the anticancer research through leading this consortiumcorresponds to our strategic plan to extend the established molecular biologyand assay development experience towards complex drug discovery research"concluded Dr. Cseh.
For further information, please visit the official web site of theCancerGrid project at http://www.cancergrid.eu as well as the TargetExwebsite: http://www.targetex.com. The project is partially financed by theCommission of the European Communities under the project number ofLSHC-CT-2006-037559.
TargetEx (formerly known as RecomGenex) was founded in 2002. Currently itis an independent company offering complex services in the early phase ofdrug discovery. Core competences of the company are protein expression, celland target-based assay development and HT screening. TargetEx offers toclients 'off the shelf' services and collaborative research and development.TargetEx recently launched a Hungarian Fragment Based Drug DiscoveryConsortium. The consortium is composed of two Hungarian biotech companies anda leading University division.
SOURCE Targetex Ltd
